Biogen to invest further $2bn in North Carolina's Research Triangle Park
The latest manufacturing investment will support the ongoing development of Biogen's late-stage clinical pipeline.
Since its establishment in 1995, the company's manufacturing in RTP has been crucial in providing innovative treatments to millions of patients globally.
The company has invested $10bn in its North Carolina manufacturing, and plans to enhance its investments in various modalities and facilities at its two campuses in RTP.
These funds will involve expanding its antisense oligonucleotide (ASO) capabilities and infrastructure, developing multi-platform fill-finish capabilities for clinical and commercial use, and further modernising manufacturing technologies and controls through AI and advanced automation.
Biogen pharmaceutical operations and technology head Nicole Murphy stated: 'We are proud of our longstanding commitment to manufacturing innovation, investment and collaboration with the Research Triangle Park community.
'Our manufacturing footprint in the US has played a critical role in Biogen's history and success, and in advancing the treatments that are making an impact for patients, families and communities here in the US and around the world.
'With this investment, we will modernise and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.'
More than 90% of the advanced commercial medicines developed by Biogen undergo manufacturing and quality control testing in the US.
In May 2025, Biogen and City Therapeutics collaborated to develop RNA interference (RNAi) therapy.
Biogen agreed to pay City Therapeutics $46m: $16m upfront and $30m investment in the form of a convertible note.
"Biogen to invest further $2bn in North Carolina's Research Triangle Park" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
17 hours ago
- Medscape
Lecanemab Preserves Memory Over 4 Years in Early AD
Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer's disease (AD) enrolled in the open-label extension of the phase 3 CLARITY AD trial. Through 4 years, lecanemab 'meaningfully' delayed progression to dementia stage of disease compared to untreated observational cohorts, said study investigator Christopher van Dyck, MD, Yale University School of Medicine, New Haven, Connecticut. With 4 years of treatment, 'there is in the vicinity of a full year's time saved' in early-stage disease. In addition, more than half of patients in the low tau subgroup showed improvement in cognitive function over time, van Dyck added. The results were presented on July 30 at the Alzheimer's Association International Conference (AAIC) 2025. Widening Benefit Over Time The core CLARITY AD trial included 1795 adults with mild cognitive impairment or early AD and confirmed amyloid pathology in the brain. Treatment consisted of IV infusions of lecanemab 10 mg/kg biweekly (n = 898) or matching placebo (n = 897). After 18 months of treatment, lecanemab slowed cognitive and functional decline, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB), by 27% compared with placebo — an absolute difference of 0.45 points ( P = .00005). To provide context, a change from 0.5 to 1.0 on the CDR score domains of memory, community affairs, and home/hobbies reflects a shift from mild impairment to loss of independence. Of the patients who completed the core 18-month study, 95% elected to continue in the open-label extension study, with 478 patients treated for 4 years. Some of these participants transitioned to once-monthly intravenous (IV) infusions, consistent with the FDA-approved regimen, and some transitioned to subcutaneous injections, a regimen currently under review by the FDA. Over 3 years of treatment, including both the core study and the open-label extension, lecanemab demonstrated a reduction in cognitive decline of 1.01 points on the CDR-SB compared to the expected decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, van Dyke reported. This benefit grew more pronounced after 4 years, with a reduction of 1.75 points compared to natural history. Similarly, when benchmarked against the expected decline in the BioFINDER cohort, lecanemab showed a reduction of 1.40 points at 3 years and 2.17 points at 4 years. Through 4 years, lecanemab reduced the relative risk of progression to next disease stage by 34% compared with ADNI; 53% of lecanemab-treated patients progressed to next disease stage vs 70% of those in the ADNI cohort. Lecanemab also reduced the relative risk of progression to dementia stage by 56%; 19% of lecanemab-treated patients progressed to dementia vs 37% of ADNI patients. Earlier Treatment Better Among participants in the tau PET substudy who had low tau levels, 69% showed improvement or no decline and 56% showed improvement from baseline on the CDR-SB after 4 years of lecanemab. Similar results were seen on the AD Assessment Scale-cognitive subscale-14; 51% of patients showed improvement or no decline, and 51% showed improvement. Likewise, on the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment, 64% of patients showed improvement or no decline, and 58% showed improvement. These findings suggest that starting and maintaining treatment with lecanemab in early-stage AD may help slow clinical decline and may provide sustained benefits over the long term, van Dyck said. No new safety signals were observed in the open-label extension phase with continued lecanemab treatment over 4 years. 'Most all of the adverse events actually go down in frequency over time, and none of them go up,' he said. Rates of amyloid-related imaging abnormalities (ARIA) decreased after the initial 12 months and remained consistent throughout four years of continuous treatment. Rates of ARIA related to edema (ARIA-E) were 13% at less than 12 months and declined to 1% at 36-48 months. Rates of ARIA related to hemorrhage (ARIA-H) were 15% at less than 12 months and 9% at 36-48 months. 'Exciting' Long-Term Data Reached for comment, Rebecca M. Edelmayer, PhD, vice president of scientific engagement for the Alzheimer's Association, told Medscape Medical News it's 'exciting to see that patients continue to show less decline and potentially even improvement in their clinical scores over time' and that the safety profile is 'consistent over time without any new types of safety events.' Edelmayer also noted that the open-label extension data from CLARITY-AD are in line with other 'real-world' data presented at AAIC 2025 from clinics using lecanemab that have demonstrated 'fairly similar safety and efficacy patterns.' Also providing perspective, Howard Fillit, MD, co-founder and chief science officer of the Alzheimer's Drug Discovery Foundation, noted that the analysis didn't have a stable control group, so the comparisons lean on historical data. But the fact that some patients improved or remained stable over time with continued lecanemab dosing is a 'major advance.' 'It's actually pretty amazing because not only has this historically been thought of as a chronic, uniformly progressive and ultimately fatal disease, but we never really thought that there would be a drug, at least I didn't, that would actually improve patients on a disease-modifying basis as this drug seems to do,' Fillit, who wasn't involved in the study, told Medscape Medical News . Fillit noted that the risk-benefit profile for lecanemab in this open-label study is 'fairly favorable. The rate of serious side effects is quite low, and I think this kind of study can help allay some of those fears about side effects.' He also noted that having a subcutaneous dosing option or lecanemab (if approved) will be a 'game changer' enabling at-home dosing and reducing the burden and inconvenience of having to go to a center to get an infusion of lecanemab. The FDA is set to decide on whether or not to approve the company's biologics license application for lecanemab subcutaneous autoinjector later this month.
Yahoo
2 days ago
- Yahoo
Biogen Inc. (BIIB): A Bull Case Theory
We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize the bulls' thesis on BIIB. Biogen Inc.'s share was trading at $131.52 as of July 25th. BIIB's trailing and forward P/E were 13.00 and 8.85 respectively according to Yahoo Finance. A scientist in a lab, researching for a breakthrough treatment for Alzheimer's disease, diabetes nephropathy, asthma, COPD, NASH, and Type 1 Diabetes. Biogen (BIIB) remains deeply unloved by the market, largely due to its missteps with the FDA on Alzheimer's drug Aduhelm, yet it continues to generate substantial and durable cash flows from its existing portfolio, with visibility for at least the next 5–10 years. The company's legacy blockbusters Tecfidera and Tysabri face erosion from generics, but overall revenue has proven more resilient than expected, while growth drivers like Leqembi are set to gain traction, potentially contributing over $5 billion in revenue over the next four years. Management has sought to bolster its relatively thin pipeline through acquisitions, most notably Reata Pharmaceuticals and its drug Skyclarys, and now has six Phase III candidates, with at least two—Tofersen and Felzartamab—showing strong prospects to become blockbusters by 2030. Despite recent challenges, Biogen delivered $2.72 billion in 2024 free cash flow, equating to a compelling 16% yield at the current market cap, with even a conservative forecast—assuming a 3% annual revenue decline through 2030 and excluding any pipeline or acquisition upside—suggesting a 10% margin of safety. Broader market conditions may also work in Biogen's favor, as the healthcare sector trades at historically low valuations, and a shift in sentiment could re-rate the stock. Near-term catalysts include stronger Leqembi uptake and one to two solid quarters that could draw institutional investors back. With shares trading in the $115–$130 range, Biogen offers an asymmetric risk/reward profile, and at sub-$115 levels appears highly attractive given its durable cash flows, undervalued pipeline, and potential for sector-wide recovery. Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive Analytics in February 2025, which highlighted resilience in profitability despite headwinds from the Inflation Reduction Act, currency impacts, and declining COVID sales. The company's stock price has appreciated by approximately 11.64% since our coverage, as the thesis played out. The thesis still stands as Gilead's fundamentals remain intact. u/Lobyous shares a similar view but emphasizes Biogen's undervaluation and catalysts from Leqembi. Biogen Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held BIIB at the end of the first quarter which was 52 in the previous quarter. While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
Earnings To Watch: Amgen (AMGN) Reports Q2 Results Tomorrow
Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here's what to look for. Amgen beat analysts' revenue expectations by 1.5% last quarter, reporting revenues of $8.15 billion, up 9.4% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' EPS estimates but full-year revenue guidance meeting analysts' expectations. Is Amgen a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Amgen's revenue to grow 6.6% year on year to $8.94 billion, slowing from the 20.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.28 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amgen has missed Wall Street's revenue estimates twice over the last two years. Looking at Amgen's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Amgen is up 1.6% during the same time and is heading into earnings with an average analyst price target of $313.48 (compared to the current share price of $297.50). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
